The U.S. Food and Drug Administration on Monday approved Tesaro Inc’s drug, niraparib, for the treatment of recurrent ovarian cancer.
Epithelial ovarian, fallopian tube or primary peritoneal cancer affects the tissue covering the ovary or lining of the fallopian tube or abdominal wall, reports Reuters.
